ArticleCardiology research2026
Association Between Insulin Resistance Marker Estimated Glucose Disposal Rate and Cardiovascular Risk in Obesity: Insights From the National Health and Nutrition Examination Survey 1999 to 2018.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated the effectiveness of the estimated glucose disposal rate (eGDR), an indicator of insulin resistance, as a screening tool for cardiovascular disease (CVD) in individuals with obesity. Methods: A cross-sectional analysis was conducted using data from the US National Health and Nutrition Examination Survey (NHANES) covering the years 1999 to 2018. The study included 20,521 participants with a waist-to-height ratio (WHtR) of 0.6 or higher, indicating obesity. Participants were divided into quartiles based on their eGDR levels: Q1 (> 8 mg/kg/min), Q2 (6 - 8 mg/kg/min), Q3 (4 - 6 mg/kg/min), and Q4 (≤ 4 mg/kg/min). Multivariable logistic regression models, adjusted for various demographic, lifestyle, and metabolic confounders, were used to analyze the relationship between eGDR and CVD. The predictive capability of eGDR was assessed using the area under the receiver operating characteristic curve (AUC), restricted cubic splines (RCS) for capturing non-linear relationships, and stratified subgroup analyses. Results: CVD prevalence significantly increased with decreasing eGDR levels (Q1: 5.3% vs. Q4: 26.2%). After full adjustment for covariates, multivariable regression confirmed that the lowest eGDR quartile (Q4) was strongly and independently associated with a substantially elevated risk of CVD compared to the highest quartile (adjusted odds ratio (OR) = 6.3; 95% confidence interval (CI): 5.53 - 7.17; P < 0.001). eGDR also demonstrated good predictive performance for specific CVD subtypes, with the highest AUC for heart failure (0.715, 95% CI: 0.699 - 0.730). RCS analysis validated a significant non-linear, inverse dose-response relationship between eGDR and overall CVD risk. Subgroup analyses, stratified by age, sex, and glycemic status, consistently demonstrated a significant association between low eGDR and increased CVD risk across all categories (P < 0.001). Conclusions: Lower eGDR independently and strongly indicated a heightened risk of CVD in individuals with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.